mDC3/8-KRAS Vaccine (University of Pennsylvania)

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NamemDC3/8-KRAS Vaccine (University of Pennsylvania)

Drug Alias NameN/A

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionImmunostimulantsV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog modulators

TargetsGTPase KRas

Therapy Area/IndicationsCarcinoma, Pancreatic Ductal

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Pennsylvania

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Pennsylvania

Inactive CompaniesN/A

Active IndicationsCarcinoma, Pancreatic Ductal

Inactive IndicationsN/A

Other Information

ATC CodeN/A